DMAC · Company research

DiaMedica Therapeutics Inc. Common Stock (DMAC): Stock News & Events

Recent company-linked news records available in the database.

RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

15records availableHealthcare

Stock News & Events data

Database-backed records only

15 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
A drug candidate was used for the first time in a trial for babies growing too slowly. Findings are set for Oct. 23. - Stock TitanA drug candidate was used for the first time in a trial for babies growing too slowly. Findings are set for Oct. 23. Stock TitanView source ↗Stock TitanSep 30, 2026neutral00.6
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - Eastern ProgressWall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet Eastern ProgressView source ↗Eastern ProgressSep 19, 2026neutral00.6
Should I buy DiaMedica Therapeutics (DMAC) - Zacks Investment ResearchShould I buy DiaMedica Therapeutics (DMAC) Zacks Investment ResearchView source ↗Zacks Investment ResearchAug 26, 2026neutral00.6
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - Yahoo FinanceWall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet Yahoo FinanceView source ↗Yahoo FinanceAug 26, 2026neutral00.6
DiaMedica Therapeutics (DMAC) Slips 1.04% as Shares Consolidate Between $6.35 Support and $7.01 Resistance - Gap and Reverse - siam.inDiaMedica Therapeutics (DMAC) Slips 1.04% as Shares Consolidate Between $6.35 Support and $7.01 Resistance - Gap and Reverse siam.inView source ↗siam.inAug 15, 2026neutral00.6
DiaMedica Therapeutics (DMAC) Edges Lower as Shares Consolidate Within Established Range - Zero Gamma Level - dars.gov.etDiaMedica Therapeutics (DMAC) Edges Lower as Shares Consolidate Within Established Range - Zero Gamma Level dars.gov.etView source ↗dars.gov.etAug 14, 2026neutral00.6
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy - Yahoo FinanceAll You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy Yahoo FinanceView source ↗Yahoo FinanceAug 13, 2026neutral00.6
DiaMedica Therapeutics (DMAC) Slips to $6.75 as Biotech Stock Consolidates Between Key Support and Resistance - Smart Beta Flow - https://www.dars.gov.et/DiaMedica Therapeutics (DMAC) Slips to $6.75 as Biotech Stock Consolidates Between Key Support and Resistance - Smart Beta Flow https://www.dars.gov.et/View source ↗https://www.dars.gov.et/Aug 8, 2026neutral00.6
(DMAC) Risk Channels and Responsive Allocation - Stock Traders Daily(DMAC) Risk Channels and Responsive Allocation Stock Traders DailyView source ↗Stock Traders DailyJul 15, 2026neutral00.6
DMAC Forecast — Price Target — Prediction for 2027 - TradingViewDMAC Forecast — Price Target — Prediction for 2027 TradingViewView source ↗TradingViewJun 25, 2026neutral00.6
DiaMedica Therapeutics Up 10%, Insider Buyers Are Up 43% - Simply Wall StreetDiaMedica Therapeutics Up 10%, Insider Buyers Are Up 43% Simply Wall StreetView source ↗Simply Wall StreetJun 24, 2026neutral00.6
$DMAC stock is down 10% today. Here's what we see in our data. - Quiver Quantitative$DMAC stock is down 10% today. Here's what we see in our data. Quiver QuantitativeView source ↗Quiver QuantitativeJan 16, 2026neutral00.6
DiaMedica Therapeutics (DMAC) Stock Forecast and Price Target 2026 - MarketBeatDiaMedica Therapeutics (DMAC) Stock Forecast and Price Target 2026 MarketBeatView source ↗MarketBeatMay 11, 2024neutral00.6
symbol__ Stock Quote Price and Forecast - CNNsymbol__ Stock Quote Price and Forecast CNNView source ↗CNNMar 3, 2024neutral00.6
DMAC Stock Price and Chart — NASDAQ:DMAC - TradingViewDMAC Stock Price and Chart — NASDAQ:DMAC TradingViewView source ↗TradingViewJan 2, 2022neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.